Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma

被引：144

作者：

Bertolini, F ^{[1
]}

Paolucci, M ^{[1
]}

Peccatori, F ^{[1
]}

Cinieri, S ^{[1
]}

Agazzi, A ^{[1
]}

Ferrucci, PF ^{[1
]}

Cocorocchio, E ^{[1
]}

Goldhirsch, A ^{[1
]}

Martinelli, G ^{[1
]}

机构：

[1] European Inst Oncol, Haematol Oncol Unit, IRCCS, I-20141 Milan, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1999年 / 106卷 / 02期

关键词：

angiogenesis; angiogenic growth factors; endostatin; non-Hodgkin's lymphoma;

D O I：

10.1046/j.1365-2141.1999.01547.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A number of clinical studies have demonstrated the prognostic significance of angiogenesis and angiogenic growth factors in solid tumours: however, very little is known about the relevance of these parameters in haematological malignancies. We evaluated circulating levels of angiogenic growth factors and endostatin in 36 non-Hodgkin's lymphoma (NHL) patients. Baseline vascular endothelial growth factor (VEGF) levels of patients in complete remission (CR) after a median follow-up of 21 months were significantly lower than those of patients with progressive disease (P=0.016). Event-free survival (EFS) rate was significantly higher in patients who had baseline VEGF and basic-fibroblast growth factor (b.FGF) levels below the median values of 147 and 19.5 pg/ml (P = 0.018 and 0.039 by log-rank test, respectively), Conversely, the levels of endostatin, angiogenin and leptin were not different in CR patients compared to relapsed patients and did not correlate with EFS. Our data suggest that b-FGF and, particularly VEGF might be considered prognostic factors in NHL staging and management.

引用

页码：504 / 509

页数：6

共 20 条

[1] Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology [J].